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TSST = toxic shock syndrome toxin; Th = T-helper (cell); TNF = tumour necrosis factor.
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Abstract
The present study demonstrates that endogenous production of IL-12 is crucial for survival in
Staphylococcus aureus-induced arthritis in mice. Staphylococcal load is enhanced in several organs,
because of lack of IL-12. This might be due to decreased production of IFN-g in IL-12-deficient mice.
Although IL-12-deficient mice were exposed to higher staphylococcal load, they demonstrated no
increased severity of arthritis as compared with control animals.
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Synopsis
Introduction: Septic arthritis is a severe disease, which is
associated with high mortality and rapid destruction of affected
joints. The most common bacterial agent in this condition is
S aureus, which is the responsible pathogen in 37–56% of all
cases of septic arthritis. Despite eradication of bacteria from
the joint cavity, destruction of the joint often continues,
resulting in severe sequelae.
In our mouse model of sepsis and septic arthritis we use an
intravenous inoculum of a S aureus strain (LS-1) that produces
toxic shock syndrome toxin (TSST)-1. This bacterial strain was
originally isolated in a mouse with spontaneous staphylococcal
arthritis. IL-12 is a heterodimeric cytokine that is composed of
the constitutively expressed p35 gene product and the
inducible p40 subunit. It is primarily produced by
monocytes/macrophages and dendritic cells.
IL-12 has a variety of effects on natural killer cells and T cells,
including the ability to facilitate T-helper (Th1)-cell responses,
and thereby IFN-g production. IFN-g has been shown to be
arthritogenic in septic arthritis, but protective with regard to
bacterial clearance and survival. IL-12 is protective in several
experimental models of bacterial infections, as demonstrated
by the fact that neutralization of this cytokine increases
susceptibility and addition of recombinant IL-12 ameliorates the
severity of the infection. However, IL-12 given at high doses
induces a septic shock-like condition, and neutralization of
IL-12 protects mice from lipopolysaccharide-induced shock.
Thus, the role of IL-12 in cases of severe bacterial infection that
culminate in septic shock is not established.
It has recently been shown that IL-12 deficiency exists in
humans and that absence of IL-12 gives rise to recurrent
infections with S aureus. The role of IL-12 in S aureus infection
has not previously been assessed. Inoculation of IL-12 p40-
deficient mice and their wild-type counterparts with a TSST-1-
producing  S aureus strain shows the critical importance of
IL-12 for survival during S aureus sepsis, in that it mediates
downregulation of staphylococcal growth.
The aim of the present study was to investigate the importance
of IL-12 in S aureus arthritis, specifically its impact on survival,
bacterial clearance and development of arthritis.
Materials and methods: Inbred male C57BL/6 mice that were
intact or defective with respect to IL-12 production were used
throughout the study. At the time of the experiment, IL-12-
deficient mice had undergone five backcrosses to C57BL/6. A
TSST-1-producing S aureus strain (LS-1), which was originallyIntroduction
Sepsis caused by S aureus is a life-threatening condition
that may cause septic shock, resulting in multiple organ
failure and ultimately death [1]. Septic arthritis is a severe
disease, involving high mortality and rapid destruction of
affected joints [2–5]. The most common bacterial agent in
this condition is S aureus, which is the responsible
pathogen in 37–56% of all cases of septic arthritis [6–8].
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isolated from a spontaneously arthritic NZB/W mouse, was
prepared according to a previously described method and was
injected into one of the tail veins.
Results: Ten days after inoculation with staphylococci all of the
IL-12–/– mice were dead, as compared with 22% of the wild-
type control animals (Fig. 1; P=0.002). These results clearly
indicate the critical importance of IL-12 production for survival
during infection with S aureus.
Bacterial growth was determined in liver, kidneys and joints 20
days after intravenous inoculation with 1×107 staphylococci/
mouse. The clearance of bacteria was clearly diminished in
IL-12-deficient mice in all three organs.
Serum levels of IFN-g were measured in IL-12-deficient mice
and wild-type control animals after intravenous inoculation of
1×10 7 staphylococci/mouse. IL-12-deficient mice displayed
decreased IFN-g levels as measured at days 7 and 20 after the
inoculation of bacteria as compared with levels in wild-type
controls (day 7, 208±83 versus 764±288U/ml; and day 20,
269±114 versus 444±170U/ml; these results were not
statistically significant).
The disruption of the p40 gene did not result in any significant
differences with regard to either the frequency or severity of
arthritis as compared with wild-type controls. The clinically
observed frequency of septic arthritis was 76% in IL-12+/+
mice, as compared to 54% in IL-12–/– animals 20 days after
inoculation of 1×107 staphylococci/mouse. Histopathological
examination confirmed the clinical data (Table 1).
Discussion: The importance of functional IL-12 during
S aureus  arthritis is demonstrated by the present study. The
major impact of IL-12 is on survival. This protection seems to
be via more efficient bacterial clearance in vivo. All arthritic
parameters, clinically and histopathologically, indicated
decreased severity in IL-12-deficient mice as compared with
wild-type controls; however, statistical significance was not
reached. It is possible that differences in joint inflammation and
erosion in response to staphylococci were more pronounced in
IL-12+/+ versus IL-12–/– mice, if the same amount of bacteria
were harboured in the joints. The levels of IFN-g are decreased
in the absence of IL-12 production, although this was not
statistically significant. This was expected, because IL-12
induces IFN-g production by natural killer cells and promotes
type 1 T-cell differentiation, cells known to produce IFN-g.
Because IFN-g is important for phagocytic functions as well as
promoting development of septic arthritis, downregulation of
IFN-g production in IL-12–/– mice may explain the outcome of
S aureus-induced arthritis..
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Table 1
Histopathological examination of joints
Synovitis Bone/cartilage destruction
IL-12 status Frequency (%) Index Frequency (%) Index
IL-12–/– 75 3.7±0.9 63 3.4±1.0
IL-12+/+ 89 5.2±1.2 78 6.2±1.7
Histopathological examination of joints from IL-12-deficient mice (n=16) and their wild-type counterparts (n=9) 20 days after intravenous
inoculation of 1×107 staphylococci/mouse. All four limbs were sectioned and stained with haematoxylin and eosin. Synovial hypertrophy or
bone/cartilage destruction was given a score of 1–3 for each joint location (elbow, wrist, carpal joints, fingers, knee, ankle, tarsal joints and toes).
Values are expressed as percentage or mean±standard error or the mean.
Figure 1
IL-12 protects against S aureus-induced death (n = 9 for both IL-12+/+
and IL-12–/–). Cumulative mortality in response to inoculation of 4 ×
108 S aureus per mouse. The experiment was finished at day 21, when
seven out of the nine IL-12+/+ were still alive.Despite eradication of bacteria from the joint cavity destruc-
tion of the joint often continues, resulting in severe sequelae
[9]. Several efforts have been made to down-modulate the
inflammatory responses that lead to septic death and arthri-
tis [10]. One problem in these attempts is the risk of
increasing staphylococcal growth in vivo. In our mouse
model of sepsis and septic arthritis, we use an intravenous
inoculum of a TSST-1-producing S aureus strain (LS-1)
[11]. This bacterial strain was originally isolated from a
mouse with spontaneous staphylococcal arthritis [12].
IL-12 is a heterodimeric cytokine that is composed of the
constitutively expressed p35 gene product and the
inducible p40 subunit [13]. It is primarily produced by
monocytes/macrophages and dendritic cells [14,15]. It
has a variety of effects on natural killer cells and T cells,
including the ability to faclitate Th1-cell responses and
thereby IFN-g production [16].
IFN-g is a classical Th1 cytokine. Modulation of IFN-g
levels using neutralizing monoclonal antibodies or addition
of recombinant cytokines show the beneficial effect of
IFN-g in terms of defence against S aureus infection,
decreasing bacterial load in tissues and increasing sur-
vival. Results from these experiments also indicate an
arthritogenic role of IFN-g in S aureus infections [17].
The role of IL-12 in several experimental models of bacter-
ial infection is protective, as demonstrated by the fact that
neutralization of this cytokine increases susceptibility and
addition of recombinant IL-12 ameliorates the severity of
the infection [18–20]. However, IL-12 given at high doses
induces a septic shock-like condition, and neutralization of
IL-12 protects mice from lipopolysaccharide-induced
shock [21,22]. Thus, the role of IL-12 in cases of severe
bacterial infection that culminate ending in septic shock is
not established. It has recently been shown that IL-12 defi-
ciency exists in humans [23] and that absence of IL-12
may give rise to recurrent infections with S aureus [24].
The role of IL-12 in S aureus infection has not previously
been assessed. Inoculation of IL-12 p40-deficient mice
and their wild-type counterparts with a TSST-1-producing
S aureus  strain demonstrates the critical importance of
IL-12 for survival during S aureus sepsis due to IL-12-
dependent downregulation of staphylococcal growth, and
the arthritogenic role of IL-12 in septic arthritis.
Materials and methods
Mice, bacteria and infection
Inbred male C57BL/6 mice that were intact or defective
with respect to IL-12 production were used throughout
the present study. IL-12 p40–/– mice were kindly provided
by Dr J Magram (Nutley, NJ, USA). The procedure of
gene disruption and mouse phenotype has previously
been described in detail [25]. At the time of experiment,
IL-12-deficient mice had undergone five back-crosses to
C57BL/6. Mice were maintained in the animal facility of
the Department of Rheumatology, University of Göteborg,
Sweden, and were kept under standard temperature and
light conditions. The mice were housed in a pathogen-
free environment. They were fed laboratory chow and
water  ad libitum.
A TSST-1-producing S aureus strain (LS-1), which was
originally isolated from a spontaneously arthritic NZB/W
mouse, was prepared according to a previously described
method [26] and injected into one of the tail veins. Two
different doses of bacteria (1×107 and 4×108 staphylo-
cocci/mouse) were used. Viable counts were used to
check the numbers of staphylococci injected.
Clinical evaluation of arthritis and weight
All mice were labelled and monitored individually. Limbs
were inspected by two observers at regular intervals (3,
7, 12 and 20 days). Arthritis was defined as visible ery-
thema and/or swelling of at least one joint. In order to
evaluate the intensity of arthritis, we used a clinical
scoring system in which macroscopic inspection yields a
score of 0–3 for each paw (0, normal; 1, mild swelling
and/or erythema; 2, moderate swelling and erythema; and
3, marked swelling and occasionally ankylosis), resulting
in an arthritic score ranging from 0 to 12 for each mouse.
An arthritic index was constructed by dividing the sum of
scores from all four limbs in each mouse by the number of
animals in each experimental group. Weight was checked
at days 0, 3, 7, 12 and 20.
Experimental protocol
In the first experiment 16 IL-12–/– mice and nine IL-12+/+
controls were inoculated intravenously with 1×107
staphylococci/mouse. Arthritis and weight were checked
at regular intervals. The experiment was finished after 20
days, when mice were bled and killed. Kidneys were
aseptically removed and bacterial growth was determined
by viable counts. All four limbs were histopathologically
examined.
In the second experiment, 21 IL-12–/– and 20 IL-12+/+ con-
trols were inoculated with 1×107 staphylococci/mouse.
Arthritis and weight were checked at regular intervals. Six
hours after staphylococcal inoculation, five mice from each
group were bled for bacterial examination and cytokine
analyses. Two days after inoculation, five mice from each
group were killed and bacterial growth in, liver, kidneys and
joints were examined. The same procedure was performed
at day 7 (IL-12–/–, n=6; IL-12+/+, n=5). The surviving mice
were bled and killed at day 20.
In a third experiment, a high dose of S aureus (4×10 8
staphylococci/mouse) were given intravenously to nine
IL-12–/– mice and nine IL-12 control animals. Survival was
checked daily.
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Microtitre plates were coated with 2mg/ml rat antimouse
IFN-g monoclonal antibodies (Pharmingen, San Diego, CA,
USA) dissolved in sodium bicarbonate (pH 9.6), and
blocked with 1% bovine serum albumin dissolved in
0.05mol/l Tris (pH 7.4) for 1h before adding samples for a
2-h incubation. Recombinant mouse IFN-g (Genzyme, Cam-
bridge, MO, USA) was used to create a standard curve.
Biotinylated rat antimouse IFN-g (2mg/ml; Pharmingen) was
employed as the capture antibody. The plates were kept for
2h at 37°C, and then incubated with streptavidin alkaline
phosphatase (Dako A/S, Glostrup, Denmark) and alkaline
phosphatase substrate 1mg/ml (Sigma, St Louis, MO,
USA). Absorbance was measured at 405nm in a Titretec
multiscan photometer (Flow Laboratories, McLean, WA,
USA). IL-10 was analyzed using an optEIA ELISA (Pharmin-
gen) Assays were performed in accordance with the manu-
facturer’s instructions, except for the addition of 2mol/l HCl,
instead of 2mol/l H2SO4.
Serum levels of IgG1, IgG2a and IgG3 were measured using
the radial immunodiffusion technique [27]. Antisera and
immunoglobulin standards were purchased from Sigma.
Determination of bacterial load
Bacterial samples from talocrural and radiocarpal joints
were obtained using cotton sticks. Bacterial presence was
defined as 15 colony-forming units or more for each joint.
The liver and both kidneys were removed aseptically,
placed on ice, homogenized and diluted in 10ml phos-
phate-buffered saline. Viable counts were performed to
determine bacterial concentration. Colonies from every
plate were then tested using a Staphaurex kit (Murex Diag-
nostcs, Dartford, UK).
Phagocytosis and intracellular killing
Intraperitoneal macrophages from noninfected mice were
extracted, adjusted to 2×106 cells/ml, and incubated in a
42-well plate (Nunc, Roskilde, Denmark) according to pro-
cedures detailed previously [28,29]. Adherent macro-
phages were incubated with 500ml S aureus at a
concentration of 5×106 bacteria/ml for 50 min at 37°C,
and were subsequently washed three times in Iscove’s
medium. Macrophage content of bacteria was then mea-
sured after two incubation intervals (0 and 4h) in order to
study phagocytosis and intracellular killing capacity,
respectively. In order to avoid extracellular bacterial growth
in the intracellular study, the incubation medium contained
10mg/ml gentamycin. The antibiotic was washed away
before lysing macrophages with distilled water.
Macrophages were extracted from three wild-type mice
and three IL-12-deficient mice. Macrophages from IL-12-
deficient animals were preincubated for 12h with 0, 10, or
100ng/ml of recombinant IL-12 (R & D Systems, Abing-
don, Oxon, UK) before adding bacteria. Supernatants were
collected from macrophage cultures before exposure to
S aureus, and after 4h of incubation with bacteria.
Histopathologic examination
Limbs were fixed in 4% paraformaldehyde, decalcified and
embedded in paraffin. Tissue sections were prepared and
stained with haematoxylin and eosin. Sections were exam-
ined by two blinded observers, who determined whether
synovial hypertrophy (membrane thickness of more than
two cell layers), pannus formation (joint cartilage covered
with synovial tissue), or destruction of cartilage and bone
were present.
Statistical analysis
Mann–Whitney U test and Fisher’s exact test were used
for statistical analyses. P<0.05 was considered statisti-
cally significant. Values are expressed as mean±standard
error of the mean.
Results
IL-12 production protects the host from fatal S aureus-
triggered sepsis
C57BL/6 mice defective (IL-12–/–) or intact (IL-12+/+) with
respect to the p40 gene, the inducible part of the het-
erodimeric IL-12 molecule, were injected intravenously
with 4×108 staphylococci/mouse. The high dose of bac-
teria used in this experiment was chosen in order to study
the influence of IL-12 on Gram-positive bacteria-triggered
septic death. No mice died within the first 4 days. The
majority of deaths occurred more than 1 week after inocu-
lation of staphylococci. Ten days after inoculation of
staphylococci, all of the IL-12–/– mice had died, as com-
pared with 22% of the wild-type control animals
(P=0.002; Fig. 1). In order to determine whether the mor-
tality rate of the IL-12+/+ mice would increase during the
later stage of infection, we terminated the experiment at 3
weeks after the bacterial inoculation. No further control
animals died during the course of the experiment. These
results clearly indicate the critical importance of IL-12 pro-
duction for survival during infection with S aureus.
Using a smaller inoculum (1×107 staphylococci/mouse)
mortality rates were overall low (IL-12-deficient mice 6%
[one out of 17] and controls 11% [one out of nine]). Inter-
estingly, with this lower dose of bacteria the weight
decrease was more pronounced in the wild-type mice as
compared with the IL-12-deficient animals in the early phase
(after 3 days) of infection (10.6% in IL-12+/+ mice versus
7.3% in IL-12–/– mice; P=0.03). The differences between
groups regarding weight change then declined, and at the
end of the experiment the wild-type mice had regained their
initial weight loss, whereas mice that lacked IL-12 produc-
tion did not (–0.3% versus –4.2%; not significant).
Influence of IL-12 deficiency on S aureus-induced
arthritis
The clinically observed frequency of septic arthritis was
76% in IL-12+/+ mice as compared with 54% in IL-12–/–
animals 20 days after inoculation of 1×107 staphylococci/
Arthritis Research    Vol 3 No 1 Hultgren et almouse. At that time, the severity of arthritis was graded as
1.3 in IL-12+/+ mice versus 0.9 in IL-12–/– mice.
Histopathological examination confirmed the clinical find-
ings (Table 1). Despite the fact that all parameters regard-
ing development of joint inflammation and destruction of
bone and cartilage indicated greater severity in mice with
an intact IL-12 gene, none of the parameters tested
reached the level of statistical significance.
Staphylococcal load is increased in several tissues due
to the absence of IL-12 production
Bacterial content was determined in liver, kidneys and joints
20 days after intravenous inoculation with 1×107 staphylo-
cocci/mouse. The clearance of bacteria was clearly dimin-
ished in IL-12-deficient mice in all three organs. A fivefold
increase in bacterial counts was seen in the livers of
IL-12–/– mice as compared with wild-type controls (Fig. 2a).
In kidneys, the bacterial load was 100-fold higher in IL-12–/–
mice as compared with IL-12+/+ controls (Fig. 2b). Finally,
S aureus was not detected in joints of IL-12+/+ mice,
whereas 75% of IL-12–/– mice had staphylococci in their
joints (Fig. 2c). We conclude that the decreased bacterial
clearance in IL-12-deficient mice as compared with in
control animals is probably the reason for the enhanced
incidence of S aureus-induced death in the former.
We also determined staphylococcal load in blood, liver and
kidneys earlier during the infection. Surprisingly, bacterial
Available online http://arthritis-research.com/content/3/1/041
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Figure 2
Effect of IL-12 on staphylococcal growth in vivo. (a) Bacterial growth in the liver, at days 2, 7 and 20 after staphylococcal inoculation. At day 2,
n = 5 in each group; at day 7, n = 6 IL-12-deficient mice and 5 control animals; and at day 20, n = 8 IL-12–/– mice and 9 wild-type controls. 
(b) Bacterial growth in the kidneys, at days 2, 7 and 20 after staphylococcal inoculation. At day 2, n = 5 in each group; at day 7, n = 6 IL-12-
deficient mice and 5 control animals; and at day 20, n = 8 IL-12–/– mice and 9 wild-type controls. (c) Frequency of mice with bacterial growth in
the joints, at days 2, 7 and 20 after staphylococcal inoculation. At day 2, n = 5 in each group; at day 7, n = 6 IL-12-deficient mice and 5 control
animals; and at day 20, n = 8 IL-12–/– mice and 9 wild-type controls. Fifteen CFU was regarded as a positive staphylococcal growth. (d) Bacterial
growth in blood, 6 h after staphylococcal inoculation; n = 5 for both IL-12+/+ and IL-12–/–.content in blood was decreased in IL-12-deficient mice as
compared with that in the wild-type control animals at 6h, as
well as in joints, liver and kidneys at 2 days after inoculation
of bacteria (Figs 2a–d). This initial beneficial effect of IL-12
deficiency on the clearance of staphylococci may explain the
significantly lower weight loss measured 3 days after bacter-
ial inoculation in IL-12–/– as compared with IL-12+/+ mice.
In order to study the importance of IL-12 on phagocytosis
and intracellular killing capacity, we extracted intraperi-
toneal macrophages from IL-12-deficient mice and their
wild-type counterparts. To simplify our method, we con-
ducted this part of the study in noninfected mice, because
in vivo activated macrophages would have encountered
different bacterial loads as a result of differences in the in
vivo clearance of S aureus, and therefore would have been
differentially activated. No differences in phagocytosis or
intracellular killing were seen (data not shown). Further-
more, recombinant mouse IL-12 (0, 10 and 100ng/ml) was
added to the IL-12-deficient macrophage cultures 12h
before exposure to staphylococci. Addition of recombinant
IL-12 did not affect either phagocytic activity or intracellular
killing (data not shown).
Decreased levels but continuous production of IFN-g g
during S aureus-induced arthritis in IL-12-deficient mice
Serum levels of IFN-g were measured in IL-12-deficient
mice and wild-type control animals after intravenous
inoculation of 1×107 staphylococci/mouse; Table 2).
IL-12-deficient mice displayed decreased IFN-g levels,
measured at days 7 and 20 after the inoculation of bacte-
ria, as compared with wild-type controls (day 7, 208±83
versus 764±288U/ml; day 20, 269±114 versus
444±170U/ml; these findings were not statistically signif-
icant). The difference in serum levels of IFN-g did not
reach statistical significance, but results at 7 and 20 days
after intravenous inoculation of S aureus indicate, as
expected, higher IFN-g levels in IL-12 p40-intact mice,
suggesting a stronger Th1 response in wild-type mice as
compared with IL-12 p40-defective mice.
Because IL-10 production is induced by IL-12 [30–33],
and IL-12-induced IL-10 production could contribute to an
explanation for the better condition of IL-12–/– mice
observed during the early phase of S aureus infection, we
analyzed serum levels of IL-10. We did not find detectable
levels of IL-10, either in IL-12+/+ or in IL-12–/– mice.
Twenty days after intravenous inoculation of staphylo-
cocci, immunoglobulin responses were higher in IL-12–/–
mice than in IL-12+/+ mice (Table 3). This was indicated by
higher serum levels of IgG1, IgG2a and IgG3 in the knock-
out mice. Notably, levels of IgG2a were not reduced, as
seen in previous studies on IL-12-deficient mice, which is
putatively due to lower levels of IFN-g [34]. Similar to the
present results, IgG2a:IgG1 ratio was not substantially
reduced in IFN-g receptor-deficient mice exposed to
superantigen-producing staphylococci [35] or in IL-12-
deficient mice subjected to viral infections [36,37]. The
increased total IgG production might be a result of a more
pronounced Th2 response, and thereby B-cell activation in
absence of IL-12 production. Alternatively, an increased
staphylococcal load in the IL-12–/– mice might have trig-
gered a more pronounced immunoglobulin production.
Discussion
The present study demonstrates that IL-12 deficiency leads
to striking increase in mortality during S aureus sepsis.
These results suggest that the presence of IL-12 is required
for efficient control of staphylococcal growth in vivo. Fur-
thermore, although exposed to higher bacterial load,
IL-12–/– mice did not display increased joint pathology.
The increased mortality of IL-12–/– mice as compared with
their wild-type counterparts was seen in parallel with an
increased staphylococcal load in the tissues examined. It
is plausible that the increased bacterial growth was the
main reason for the sharply increased death rates in the
absence of IL-12 production.
In order to determine whether IL-12 itself had any direct
effect on the phagocytosis and/or intracellular killing
capacity, we employed two different approaches using
intraperitoneal macrophages from IL-12–/– and IL-12+/+
Arthritis Research    Vol 3 No 1 Hultgren et al
Table 2
Serum levels of IFN-g
Days after staphylococcal inoculation
IL-12 status 2 7 20
IL-12+/+ 12±5 764±288 444±170
IL-12–/– 46±17 208±83 269±114
Serum levels of IFN-g in IL-12-deficient mice (day 2, n=5; day 7, n=5;
day 20, n=9) and wild-type controls (day 2, n=5; day 7, n=6; day 20,
n=16) after intravenous inoculation of 1×107 staphylococci/mouse.
Values are expressed as mean±standard error of the mean (units/ml).
Table 3
Serum IgG isotypes in response to TSST-1 secreting
Staphylococcus aureus
IgG isotype
IL-12 status IgG1 IgG2a IgG3
IL-12–/– 5.9±1.1 1.8±0.4* 1.2±0.2
IL-12+/+ 4.3±0.4 0.86±0.0 0.97±0.15
Levels measured in sera 20 days after inoculation of bacteria. Values
are expressed as mean±standard error of the mean (mg/ml). IL-12–/–,
n=16; IL-12+/+, n=8. *P=0.03.mice. No differences in intracellular killing of bacteria were
seen. Indeed, supplementing IL-12–/– macrophages with
recombinant IL-12 neither affected the uptake nor killing of
staphylococci. This is in contrast to the beneficial antifun-
gal effects that IL-12 p40–/– macrophages exert during
infection with Candida albicans [38].
IL-12 is known to induce development of Th1 cells and
their subsequent differentation to produce IFN-g [39]. A
recent study [17] showed the importance of IFN-g in
recruitment of neutrophils and the increased phagocytosis
during staphylococcal infection. Macrophages, despite
not being a major producer of IFN-g, have been shown to
synthesize this cytokine after stimulation with IL-12 and
IL-18, but not with IL-12 alone [40]. This might have been
the main reason for the lack of direct effect of IL-12 on
staphylococcal growth in vitro. In vivo data showing
decreased serum levels of IFN-g in IL-12–/– mice as com-
pared with IL-12+/+ control animals support deficient
IL-12-dependent IFN-g production as an explanation for
the decreased bacterial clearance in IL-12–/– mice. It is
thus plausible that IL-12 is protective with regard to
S aureus-triggered death via enhanced phagocytic activity
mediated by IFN-g.
An alternative or parallel explanation for the observed
effect of IL-12 deficiency on decreased survival during
S aureus-induced sepsis is the previously described
effects of this cytokine on IL-10 production. IL-12 induces
IL-10 production, and thereby downregulates production
of tumour necrosis factor (TNF), IFN-g and nitric oxide
[41], with TNF and IFN-g being detrimental in septic shock
[42–44]. Indeed, supplementation with recombinant IL-10
protects against death both from lipopolysaccharide-trig-
gered enotoxemic shock [45,46] and staphylococcal
enterotoxin B-induced shock [47]. This might be relevant
because the higher bacterial cell counts in IL-12-deficient
mice potentially lead to increased production of TSST-1
as compared with controls. However, we were not able to
detect IL-10 production in IL-12+/+ or IL-12–/– mice,
despite analyzing serum at several time points after bacte-
rial inoculation. Downregulated IL-10 production in the
absence of IL-12 could be a reason for the enhanced bac-
terial clearance seen in IL-12-deficient mice as compared
with controls during the early phase of S aureus infection.
It is somewhat surprising that, although IL-12-deficient
mice have a defect in bacterial clearance and therefore
are exposed to a higher staphylococcal load than their
wild-type counterparts, they did not develop a more
severe septic arthritis, but rather milder joint involvement.
A similar outcome has previously been shown using
TNF/lymphotoxin-a double mutants [48]. The mechanisms
that underlie these results may again be explained by the
decreased production of IFN-g in IL-12–/– mice versus
IL-12+/+ animals. Previous studies implicate IFN-g as a
cytokine that promotes induction of septic arthritis, in addi-
tion to its importance in phagocytic activity.
The present results clearly demonstrate the critical role
played by endogenous IL-12 in preventing death during
S aureus-induced arthritis. The protection results from
decreasing the bacterial load, an effect that is possibly due
to IL-12-dependent IFN-g mediation of phagocytic activity.
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